Hunting and trapping the vascular endothelial growth factor

Journal of Clinical Oncology

Volumn 28, Issue 2, 2010, Pages 185-187

  Dowlati, Afshin ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CEDIRANIB; PAZOPANIB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ASTHENIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG BINDING; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG MEGADOSE; EDITORIAL; GLIOBLASTOMA; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECOMMENDED DRUG DOSE; TREATMENT RESPONSE; DRUG DELIVERY SYSTEM; NOTE;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 74949105993     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.4359     Document Type: Editorial

References (21)

1. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003
2. Holash J, Davis S, Papadopoulos N, et al: VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393-11398, 2002
3. Lockhart AC, Rothenberg ML, Dupont J, et al: Phase I study of intravenous vascular endothelial growth factor trap (aflibercept) in patient with advanced solid tumors. J Clin Oncol 28:207-214, 2010
4. Dupont J, Camastra D, Gordon MS, et al: Phase 1 study of VEGF Trap in patients with solid tumors and lymphoma. Proc Am Soc Clin Oncol 22:194, 2003 (suppl; abstr 776)
5. Hurwitz HI, Dowlati A, Saini S, et al: Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15:4220-4227, 2009
6. Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972, 2005
7. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006
8. Gordon MS, Margolin K, Talpaz M, et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001
9. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
10. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
11. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
12. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
13. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
14. Kreisl TN, Kim L, Moore K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
15. De Groot JF, Wen PY, Lamborn K, et al: Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. J Clin Oncol 26:94s, 2008 (suppl; abstr 2020)
16. Massarelli E, Miller VA, Leighl NB, et al: Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung. J Clin Oncol 25:416s, 2007 (suppl 18S; abstr 7627)
17. Tew WP, Colombo N, Ray-Coquard I, et al: VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol 25:276s, 2007 (suppl 18S; abstr 5508)
18. Tarhini AA, Christensen S, Frankel P, et al: Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin. J Clin Oncol 27:468s, 2009 (suppl 15S; abstr 9028)
19. Hanna NH, von Pawel J, Reck M, et al: Carboplatin/paclitaxel with/without sorafenib in chemonaive patients with stage IIIB-IV non-small-cell lung cancer: Interim analysis results from a randomized phase III trial (ESCAPE). J Thorac Oncol 3:S268, 2008 (suppl)
20. Kim ES, Serur A, Huang J, et al: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 99:11399-11404, 2002
21. Dowlati A, Gray R, Sandler AB, et al: Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: An Eastern Cooperative Oncology Group Study. Clin Cancer Res 14:1407-1412, 2008